1556: Sonpavde G, Wang M, Peterson LE, Wang HY, Joe T, Mims MP, Kadmon D, Ittmann
MM, Wheeler TM, Gee AP, Wang RF, Hayes TG. HLA-restricted NY-ESO-1 peptide
immunotherapy for metastatic castration resistant prostate cancer. Invest New
Drugs. 2014 Apr;32(2):235-42. doi: 10.1007/s10637-013-9960-9. Epub 2013 Apr 23.
PubMed PMID: 23609828; PubMed Central PMCID: PMC4100683.


1557: Sonpavde G, Kantoff PW. Immunotherapy for castration-resistant prostate
cancer. Urol Clin North Am. 2012 Nov;39(4):465-81. doi:
10.1016/j.ucl.2012.07.004. Review. PubMed PMID: 23084524.


1558: Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND. The
role of sipuleucel-T in therapy for castration-resistant prostate cancer: a
critical analysis of the literature. Eur Urol. 2012 Apr;61(4):639-47. doi:
10.1016/j.eururo.2011.10.027. Epub 2011 Oct 24. Review. PubMed PMID: 22036643.


1559: Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW. Recent advances in
immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther. 2011
Aug;11(8):997-1009. doi: 10.1517/14712598.2011.575357. Epub 2011 Jun 15. Review. 
PubMed PMID: 21675925.


1560: Sonpavde G, Slawin KM, Spencer DM, Levitt JM. Emerging vaccine therapy
approaches for prostate cancer. Rev Urol. 2010 Winter;12(1):25-34. PubMed PMID:
20428291; PubMed Central PMCID: PMC2859139.


1561: Sonpavde G, Spencer DM, Slawin KM. Vaccine therapy for prostate cancer.
Urol Oncol. 2007 Nov-Dec;25(6):451-9. Review. PubMed PMID: 18047951.